BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 2014;32:4938-44. [DOI: 10.1016/j.vaccine.2014.07.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Kouiavskaia D, Puligedda RD, Dessain SK, Chumakov K. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. J Virol Methods 2020;276:113785. [PMID: 31765719 DOI: 10.1016/j.jviromet.2019.113785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D. Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine. PLoS Pathog 2016;12:e1005483. [PMID: 27032093 DOI: 10.1371/journal.ppat.1005483] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
3 Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, Yin W. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial. J Infect Dis 2019;220:1551-7. [PMID: 30958543 DOI: 10.1093/infdis/jiy736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
4 Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, Ying Z, Wang J, Yang H, Ma Y, Ma L, Ji G, Shi L, Jiang S, Li Q. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses. Clinical Infectious Diseases 2017;64:1317-25. [DOI: 10.1093/cid/cix110] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
5 Leroux-Roels I, Leroux-Roels G, Shukarev G, Schuitemaker H, Cahill C, de Rooij R, Struijs M, van Zeeburg H, Jacquet JM. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults. Hum Vaccin Immunother 2021;17:1366-73. [PMID: 33175637 DOI: 10.1080/21645515.2020.1812315] [Reference Citation Analysis]
6 Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, Yang J, Yin Z, Wang J, Chu J, Cai W, Zhou J, Wang J, Li Q. Phase 3 Trial of a Sabin Strain–Based Inactivated Poliovirus Vaccine. J Infect Dis 2016;214:1728-34. [DOI: 10.1093/infdis/jiw433] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
7 Kanojia G, ten Have R, Brugmans D, Soema PC, Frijlink HW, Amorij J, Kersten G. The effect of formulation on spray dried Sabin inactivated polio vaccine. European Journal of Pharmaceutics and Biopharmaceutics 2018;129:21-9. [DOI: 10.1016/j.ejpb.2018.05.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Resik S, Tejeda A, Fonseca M, Sein C, Hung LH, Martinez Y, Diaz M, Okayasu H, Sutter RW. Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies. Trials Vaccinol 2015;4:71-4. [PMID: 27066157 DOI: 10.1016/j.trivac.2015.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016;34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
10 Sanders BP, Liu Y, Brandjes A, van Hoek V, de Los Rios Oakes I, Lewis J, Wimmer E, Custers JHHV, Schuitemaker H, Cello J, Edo-Matas D. Brunenders: a partially attenuated historic poliovirus type I vaccine strain. J Gen Virol 2015;96:2614-22. [PMID: 26018960 DOI: 10.1099/vir.0.000197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, Rüttimann R, Modlin JF, Gast C. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine 2017;35:7283-91. [PMID: 29150209 DOI: 10.1016/j.vaccine.2017.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Li Z, Ding W, Guo Q, Liu Z, Zhu Z, Song S, Li W, Liao G. Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV). Hum Vaccin Immunother 2018;14:1987-94. [PMID: 29601259 DOI: 10.1080/21645515.2018.1454571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Nakano T, Sumino S, Takanami Y, Mitsuya N, Nakatome K. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. Hum Vaccin Immunother 2018;14:2940-9. [PMID: 30047808 DOI: 10.1080/21645515.2018.1504538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Chan HT, Xiao Y, Weldon WC, Oberste SM, Chumakov K, Daniell H. Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes. Plant Biotechnol J 2016;14:2190-200. [PMID: 27155248 DOI: 10.1111/pbi.12575] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
15 Bai H, Liu S, Shi S, Lu W, Yang Y, Zhu Y, Zhang Z, Guo H, Li X. Identification of the epitope in human poliovirus type 1 Sabin strain recognized by the monoclonal antibody 1G10 using mimotope strategy. J Virol Methods 2020;276:113791. [PMID: 31778678 DOI: 10.1016/j.jviromet.2019.113791] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW. Development of inactivated poliovirus vaccine from Sabin strains: A progress report. Biologicals 2016;44:581-7. [DOI: 10.1016/j.biologicals.2016.08.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
17 Thomassen YE, Bakker WA. sIPV process development for costs reduction. Vaccine 2015;33:4307-12. [DOI: 10.1016/j.vaccine.2015.03.076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Sutter RW, Okayasu H, Kieny MP. Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived. Clin Infect Dis 2017;64:1326-7. [PMID: 28200099 DOI: 10.1093/cid/cix116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Parker EP, Molodecky NA, Pons-Salort M, O'Reilly KM, Grassly NC. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines 2015;14:1113-23. [PMID: 26159938 DOI: 10.1586/14760584.2015.1052800] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
20 Kraan H, Soema P, Amorij JP, Kersten G. Intranasal and sublingual delivery of inactivated polio vaccine. Vaccine 2017;35:2647-53. [PMID: 28400164 DOI: 10.1016/j.vaccine.2017.03.090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Xiao Y, Daniell H. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines. Vaccine 2017;35:5418-25. [PMID: 28111147 DOI: 10.1016/j.vaccine.2016.12.061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
22 Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, Han S, Wittawatmongkol O. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis 2020:jiaa770. [PMID: 33351072 DOI: 10.1093/infdis/jiaa770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, Xie S, Wen N, An Z, Chen Z, Wang H. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis 2020;20:1071-9. [PMID: 32442523 DOI: 10.1016/S1473-3099(19)30738-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
24 Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791-808. [PMID: 25824845 DOI: 10.2217/fmb.15.19] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 19.2] [Reference Citation Analysis]
25 Decker MD, Edwards KM, Howe BJ. Combination Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 198-227.e13. [DOI: 10.1016/b978-0-323-35761-6.00015-8] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Sáez-Llorens X. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial. Vaccine 2020;38:5313-23. [PMID: 32563609 DOI: 10.1016/j.vaccine.2020.05.081] [Reference Citation Analysis]
27 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]